Estimated dispatch within 24 working hours.
Species: Dogs Therapeutic indication: Pharmaceuticals: Neurological preparations: General anaesthetics Active ingredient: Sevoflurane Product:SevoFlo® 100% w/w Inhalation vapour, liquid for dogs Product index: SevoFlo
SevoFlo is an inhalation vapour, as liquid, containing 100% sevoflurane per ml.
Indicated for the induction and maintenance of anaesthesia in dogs.
SevoFlo should be administered via a vaporiser specifically calibrated for use with sevoflurane so that the concentration delivered can be accurately controlled. SevoFlo contains no stabiliser and does not affect the calibration or operation of these vaporisers in any way. The administration of sevoflurane must be individualised based on the dog's response.
The necessity for and choice of premedication is left to the discretion of the veterinarian. Preanaesthetic doses for premedicants may be lower than the label directions for their use as a single medication.
For mask induction using sevoflurane, inspired concentrations of 5 to 7% sevoflurane with oxygen are employed to induce surgical anaesthesia in the healthy dog. These concentrations can be expected to produce surgical anaesthesia within 3 to 14 minutes and may be set initially, or may be achieved gradually over the course of 1 to 2 minutes. The use of premedicants does not affect the concentration of sevoflurane required for induction.
Sevoflurane may be used for maintenance anaesthesia following mask induction with sevoflurane or following induction with injectable agents. The concentration of sevoflurane necessary to maintain anaesthesia is less than that required for induction. Surgical levels of anaesthesia in the healthy dog may be maintained with inhaled concentrations of 3.3 to 3.6% in the presence of premedication. In the absence of premedication, inhaled concentrations of sevoflurane in the range 3.7 to 3.8% will provide surgical levels of anaesthesia in the healthy dog. The presence of surgical stimulation may require an increase in the concentration of sevoflurane. The use of injectable induction agents without premedication has little effect on the concentrations of sevoflurane required for maintenance. Anaesthetic regimens that include opioid, alpha-2-agonist, benzodiazepine or phenothiazine premedication will allow the use of lower sevoflurane maintenance concentrations.
Do not use in dogs with known hypersensitivity to sevoflurane or other halogenated anaesthetic agents. Do not use in pregnant and lactating bitches. The safety of SevoFlo has not been established during pregnancy and lactation. However, there is limited clinical experience of the use of sevoflurane, after propofol induction, in bitches undergoing caesarean section, without any ill effects being detected in either the bitch or the puppies. Use only according to the risk/benefit assessment of the responsible veterinarian. Do not use in dogs with a known or suspected susceptibility to malignant hyperthermia. Do not use in dogs less than 12 weeks of age. The most frequently reported adverse reactions associated with SevoFlo administration were hypotension, followed by tachypnoea, muscle tenseness, excitation, apnoea, muscle fasciculations and emesis. Sevoflurane causes dose-dependent respiratory depression, therefore respiration should be closely monitored during sevoflurane anaesthesia and the inspired concentration of sevoflurane adjusted accordingly. The use of some anaesthetic regimens that include sevoflurane may result in bradycardia that is reversible with anticholinergics. Infrequent adverse reactions include paddling, retching, salivation, cyanosis, premature ventricular contractions and excessive cardiopulmonary depression. Transient elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), bilirubin and white blood cell counts may occur with sevoflurane, as with the use of other halogenated anaesthetic agents. Hypotension during sevoflurane anaesthesia may result in decreased renal blood flow. The possibility of sevoflurane triggering episodes of malignant hyperthermia in susceptible dogs cannot be ruled out. SevoFlo overdose may result in profound respiratory depression. Therefore, respiration must be monitored closely and supported when necessary with supplementary oxygen and/or assisted ventilation. In cases of severe cardiopulmonary depression, administration of sevoflurane should be discontinued, the existence of a patent airway ensured, and assisted or controlled ventilation with pure oxygen initiated. Cardiovascular depression should be treated with plasma expanders, pressor agents, antiarrhythmic agents or other appropriate techniques. Due to sevoflurane's low solubility in blood, increasing the concentration may result in rapid haemodynamic changes (dose-dependent decreases in blood pressure) compared to other volatile anaesthetics. Excessive decreases in blood pressure or respiratory depression may be corrected by decreasing or discontinuing the inspired concentration of sevoflurane. Halogenated volatile anaesthetics can react with dry carbon dioxide (CO2) absorbents to produce carbon monoxide (CO) that may result in elevated levels of carboxyhaemoglobin in some dogs. In order to minimise this reaction in rebreathing anaesthetic circuits, SevoFlo should not be passed through soda lime or barium hydroxide that has been allowed to dry out. The exothermic reaction that occurs between inhalation agents (including sevoflurane) and CO2 absorbents is increased when the CO2 absorbent becomes desiccated, such as after an extended period of dry gas flow through the CO2 absorbent canisters. Rare cases of excessive heat production, smoke and/or fire in the anaesthetic machine have been reported during the use of a desiccated CO2 absorbent and sevoflurane. An unusual decrease in the expected depth of anaesthesia compared to the vaporiser setting may indicate excessive heating of the CO2 absorbent canister. If it is suspected that the CO2 absorbent may be desiccated, it must be replaced. The colour indicator of most CO2 absorbents does not necessarily change as a result of desiccation. Therefore, the lack of significant colour change should not be taken as an assurance of adequate hydration. CO2 absorbents should be replaced routinely regardless of the state of the colour indicator. 1,1,3,3,3-pentafluoro-2-(fluoromethoxy)propene (C4H2F6O), also known as Compound A, is produced when sevoflurane interacts with soda lime or barium hydroxide. Reaction with barium hydroxide results in a greater production of Compound A than does the reaction with soda lime. Its concentration in a circle absorber system increases with increasing sevoflurane concentrations and with decreasing fresh gas flow rates. Sevoflurane degradation in soda lime has been shown to increase with temperature. Since the reaction of carbon dioxide with absorbents is exothermic, this temperature increase will be determined by the quantities of CO2 absorbed, which in turn will depend on fresh gas flow in the anaesthetic circle system, metabolic status of the dog and ventilation. Although Compound A is a dose-dependent nephrotoxin in rats, the mechanism of this renal toxicity is unknown. Long-duration, low-flow sevoflurane anaesthesia should be avoided due to the risks of Compound A accumulation. During maintenance of anaesthesia, increasing the concentration of sevoflurane produces a dose-dependent decrease in blood pressure. Due to sevoflurane's low solubility in blood, these haemodynamic changes may occur more rapidly than with other volatile anaesthetics. Arterial blood pressure should be monitored at frequent intervals during sevoflurane anaesthesia. Facilities for artificial ventilation, oxygen enrichment and circulatory resuscitation should be immediately available. Excessive decreases in blood pressure or respiratory depression may be related to the depth of anaesthesia and may be corrected by decreasing the inspired concentration of sevoflurane. The low solubility of sevoflurane also facilitates rapid elimination by the lungs. The nephrotoxic potential of certain NSAIDs, when used in the perioperative period, may be exacerbated by hypotensive episodes during sevoflurane anaesthesia. In order to maintain renal blood flow, prolonged episodes of hypotension (mean arterial pressure below 60 mmHg) should be avoided in dogs during sevoflurane anaesthesia. If malignant hyperthermia develops, the anaesthetic supply should be interrupted immediately and 100% oxygen administered using fresh anaesthetic hoses and a rebreathing bag. Appropriate treatment should readily be instituted.
Doses of sevoflurane may need adjustment for geriatric or debilitated dogs. Doses required for maintenance anaesthesia may need to be reduced by approximately 0.5% in geriatric dogs (i.e. 2.8% to 3.1% in premedicated geriatric dogs and 3.2 to 3.3% in unpremedicated geriatric dogs). Limited clinical experience in administering sevoflurane to dogs with renal, hepatic and cardiovascular insufficiency suggests that sevoflurane may be safely used in these conditions. However, it is recommended that such animals be monitored carefully during sevoflurane anaesthesia. Sevoflurane may cause a small increase in intracranial pressure (ICP) under conditions of normocapnia. In dogs with head injuries or other conditions placing them at risk from increased ICP, it is recommended that hypocapnia be induced by means of controlled hyperventilation as a means of preventing changes in ICP.
In order to minimise exposure to sevoflurane vapour, the following recommendations are made: •Use a cuffed endotracheal tube when possible for the administration of SevoFlo during maintenance anaesthesia. •Avoid using masking procedures for prolonged induction and maintenance of general anaesthesia. •Ensure that operating rooms and animal recovery areas are provided with adequate ventilation or scavenging systems to prevent the accumulation of anaesthetic vapour. •All scavenging/extraction systems must be adequately maintained. •Pregnant and breast-feeding women should not have any contact with the product and should avoid operating rooms and animal recovery areas. •Care should be taken when dispensing SevoFlo, with immediate removal of any spillage. •Do not inhale the vapour directly. •Avoid contact by mouth. •Halogenated anaesthetic agents may induce liver damage. This is an idiosyncratic response very occasionally seen after repeated exposure. •From an environmental point of view, it is considered good practice to use charcoal filters with scavenging equipment. Direct exposure to eyes may result in mild irritation. If eye exposure occurs, the eye should be flushed with plenty of water for 15 minutes. Medical attention should be sought if irritation persists. In case of accidental contact with the skin, wash affected area with abundant water. Symptoms of human overexposure (inhalation) to sevoflurane vapour include respiratory depression, hypotension, bradycardia, shivering, nausea and headache. If these symptoms occur, the individual should be removed from the source of exposure and medical attention sought. Advice to doctors: Maintain a patent airway and give symptomatic and supportive treatment.
Do not store above 25°C. Do not refrigerate. Keep the bottle tightly closed. Any unused product or waste materials should be disposed of in accordance with national requirements. Keep out of the sight and reach of children. For animal treatment only.
Legal category: POM-V
Supplied in a 250 ml polyethylene naphthalate (PEN) bottle with a Quik-Fil closure.
Sevoflurane administration is compatible with the intravenous barbiturates and propofol. The concurrent administration of thiopental, however, may slightly increase sensitivity to adrenaline-induced cardiac arrhythmias. Sevoflurane administration is compatible with benzodiazepines and opioids commonly used in veterinary practice. In common with other inhalational anaesthetics, the MAC of sevoflurane is reduced by the concurrent administration of benzodiazepines and opioids. Sevoflurane is compatible with phenothiazines and alpha-2-agonists commonly used in veterinary practice. Αlpha-2-agonists have an anaesthetic sparing effect and therefore the dose of sevoflurane should be reduced accordingly. Limited data are available on the effects of the highly potent alpha-2-agonists (medetomidine and romifidine) as premedication. Therefore they should be used with caution. Bradycardia may develop when alpha-2-agonists are used with sevoflurane. Bradycardia can be reversed by the administration of anticholinergics. Studies using sevoflurane anaesthetic protocols that included atropine or glycopyrrolate as premedicants showed these anticholinergics to be compatible with sevoflurane in dogs. In a laboratory study, the use of an acepromazine/oxymorphone/thiopental/sevoflurane anaesthetic regimen resulted in prolonged recoveries in all the dogs treated, compared to recoveries in dogs anaesthetised with sevoflurane alone. The use of sevoflurane with non-depolarising muscle relaxants has not been evaluated in dogs. However, in humans the use of sevoflurane increases both the intensity and duration of neuromuscular blockade induced by non-depolarising muscle relaxants.
GTIN description:250 ml: GTIN:05414736031446
All prices include VAT where applicable.
There are currently no questions for SevoFlo 100% w/w Inhalation vapour, liquid for dogs - be the first to ask one!Ask A Question
Sorry that this product is out of stock, instead of having to keep checking back to see if we have it, we can send you a notification as soon as it comes back in stock.
We won't use any details you enter for any other purpose than letting you know when this is back in stock.
Please enter details for each method you'd like us to notify you by:
VioPoints are a way for us to say thank you for purchasing from VioVet.
You will receive VioPoints by purchasing this product, which can be redeemed for a discount on future purchases. For each 1000 points redeemed at the checkout, you will receive a 20p discount.
The number of VioPoints is shown on the product listing and they are awarded on dispatch of the order.
Terms and conditions apply.